ABC Partner Hub

How to position Cylinder Health with employers

Clear, executive-ready summary

What clients can expect to achieve

MNPS

US Foods

National Health Plan

Digestive health isn’t just a personal issue—it’s a silent, costly driver of absenteeism, disengagement, and escalating health care claims. For women, it’s more complex and often overlooked. Conditions like IBS, IBD, and GERD affect women at far higher rates, yet stigma and care gaps leave many without effective support.

This guide from Cylinder breaks the silence and shows how inclusive digestive care can be the missing piece in your women’s health strategy—delivering measurable impact without overhauling your existing benefits.

Biologics are driving GI costs. But they’re not the real problem.

Inflammatory bowel disease (IBD) is one of the costliest, most complex conditions in many health plan populations, driven by diagnostic delays, fragmented care, and late stage escalation to high cost drugs.

Biologics can exceed $100K per member per year, and once started, many patients remain on therapy for years. Attempts to restrict access can backfire, leading to relapse, ED visits, and higher total cost of care.

The fix isn’t less care. It’s smarter care.

Plans need earlier detection, better triage, and integrated GI support that complements biologic therapy rather than reacting after costs escalate.

Inside the whitepaper, you’ll learn:

• Why biologics alone aren’t solving IBD and what’s missing.
• How delayed GI care inflates pharmacy and ED spend.
• What plans can do today to reduce cost without restricting access.
• Real-world results, including 25% drop in GI pharmacy spend.